The table below shows Aquestive Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$14.45M
$12.81M
$10.00M
$8.72M
$13.54M
$20.10M
Cost of revenue
$3.47M
$4.51M
$4.56M
$3.65M
$4.44M
$4.53M
Gross profit
-
-
-
-
-
-
R&D
$4.20M
$4.53M
$4.11M
$5.36M
$5.27M
$4.16M
AQST annual revenue (10-K history)
Aquestive Therapeutics, Inc. reported annual revenue of $44.55M for fiscal year 2025. That is down 22.6% from $57.56M in fiscal 2024. Over the 9 fiscal years shown, annual revenue declined from $66.92M (FY 2017) to $44.55M. Figures come from the company's audited annual reports as filed with the SEC.